Shanghai Techwell Biopharmaceutical Co., Ltd.

Zhijun Tang

Xiaoming Ji

Bingming He

Jun Zhu

Shidong Liu

Zhonghao Zhuo

Jun Yang

Xiaoliang Gao

Xiusheng Wang

Yunman Zheng

Yubin Liu

Xiao Xun Zhang

Zhaoli Zhang

Tianhui Xu

Xiao Zhang

Guangjun Jiao

Huichun Yang

Jushang Zheng

Ming Li

Disclosed is a crystalline powder of a cyclic peptide compound, represented by formula I is the structure of same, and, also disclosed are a preparation method for same and uses thereof. 

Crystalline powder of cyclic peptide compound, preparation method for same, and uses thereof

A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal. 

High-purity cyclopeptide crystal as well as preparation method and use thereof

Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or salts thereof into a system of water and acetic acid, then mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline.

Caspofungin or salts thereof with high purity, as well as preparation method and use thereof

Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9&#xb1;0.2&#xb0;, 6.5&#xb1;0.2&#xb0;, 12.6&#xb1;0.2&#xb0;, 13.1&#xb1;0.2&#xb0; and 20.6&#xb1;0.2&#xb0;. 

Crystal form of prostaglandin analogue, and preparation method and use thereof

Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9&#xb1;0.2&#xb0;, 13.6&#xb1;0.2&#xb0;, 17.3&#xb1;0.2&#xb0; and 18.6&#xb1;0.2&#xb0;. 

A purification method of the compound represented by formula 1 is provided, which includes the following steps: (1) loading crude compound 1 on macroporous adsorbent resin, (2) washing the macroporous adsorbent resin with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water, (3) eluting with an aqueous solution, an organic solvent or a mixture solution of organic solvent and water. The purified compound represented by formula 1 is obtained. 

Purification method of azacyclohexapeptide or its salt

The method of the preparation of micafungin sodium comprises the step of mixing the weak base and the aqueous solution containing micafungin acid (the structure is illustrated by formula I) or the mixed aqueous solution containing the compound of formula I and organic solvent in order to obtain the sodium salt of micafungin (the structure is illustrated by formula II). 

Preparation method of micafungin sodium

Disclosed are a caspofungin analog, and a preparation method and applications thereof. The caspofungin analog has a structure as represented in Formula 3. 

Caspofungin analog, and preparation method and uses thereof

Disclosed are a caspofungin analog and applications thereof. The caspofungin analog is a compound having a structure as indicated in Formula (4), or pharmaceutically acceptable salts thereof. Rcan be chosen from hydroxyl, benzyloxy, phenoxy, substituted phenoxy, or substituted benzyloxy. R, R, R, Rcan be chosen from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, benzyloxyphenyl, substituted benzyloxyphenyl, nitro, fluorine, chlorine, bromine, or iodine. Also disclosed are a preparation method for and applications of the compound. 

Caspofungin analog and applications thereof

Disclosed is a preparation method for caspofungin, comprising the steps: (a) a compound as represented in Formula 2 and a strong leaving group 5 are mixed to obtain a compound as represented in Formula 3; (b) the compound as represented in Formula 3 and ethylenediamine are mixed to obtain a compound as represented in Formula 4; and, (c) the compound as represented in Formula 4 is mixed with a hydroxyl protection agent, and then a borane complex is mixed in to obtain a compound as represented in Formula 1.

Preparation method for caspofungin

The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction pattern of said crystal comprises characteristic peaks measured at the following 2&#x3b8; reflection angles: 14.6&#xb1;0.2&#xb0;, 17.0&#xb1;0.2&#xb0; and 19.6&#xb1;0.2&#xb0;. As compared to amorphous lubiprostone, the crystal of the present invention has the advantages of relative high purity, stable properties and easy-for-storage and use.

Lubiprostone crystal, the use and the method for the preparation thereof

The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2&#x3b8; are 3.2&#xb1;0.2&#xb0;, 5.5&#xb1;0.2&#xb0;, 11.4&#xb1;0.2&#xb0;, 16.7&#xb1;0.2&#xb0;, 17.6&#xb1;0.2&#xb0;, 19.9&#xb1;0.2&#xb0;, 20.8&#xb1;02&#xb0; and 22.8&#xb1;0.2&#xb0; in the X-ray powder diffraction pattern of the crystalline form A.

Growing community of inventors

Shanghai, China

Zhijun Tang